References
1.https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020(Accessed 27-Mar-2020).
2. https://www.worldometers.info/coronavirus/ (Accessed 15-May-2020).
3. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020 Mar 5. doi: 10.1002/jmv.25748.
4. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269.
5. Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19 infection and mortality - A physiologist’s perspective enlightening clinical features and plausible interventional strategies. Am J Physiol Lung Cell Mol Physiol. 2020 Mar 24.doi:10.1152/ajplung.00097.2020.
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr 13. doi: 10.1001/jama.2020.6019.
7. Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist. 2020;21:22-27.
8. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.
9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Mar 11. pii: S2213-2600(20)30116-8. doi: 10.1016/S2213-2600(20)30116-8.
10. Halpin D, Faner R, Sibila O, Badia J, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020 April 3, 2020.https://doi.org/10.1016/S2213-2600(20)30167-3.
11. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China - Summary of a report of 72 314 cases from the chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
12. Lu X, Zhang L, Du H, et al; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 infection in children. N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMc2005073.
13. Zheng F, Liao C, Fan QH, et al. Clinical characteristics of children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275-280.
14. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.
15. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238.
16. Zhang JJ, Cao Y, Dong X, et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy. 2020. DOI: 10.1111/all.14316.
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 11. pii: S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3.
18. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Apr 12. pii: S0091-6749(20)30495-4. doi: 10.1016/j.jaci.2020.04.006.
19. Guan WJ, Liang WH, Zhao Y, et al; China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J. 2020 Mar 26. pii: 2000547. doi: 10.1183/13993003.00547-2020.
20. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 Mar 23. doi: 10.1001/jama.2020.4683.
21. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6. doi: 10.1001/jama.2020.5394.
22. Niccolò Parri, Matteo Lenge, Danilo Buonsenso, for the Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020. DOI: 10.1056/NEJMc2007617.
23. Borobia AM, Carcas AJ, Arnalich F, et al; for the COVID@HULP Working Group. A cohort of patients with COVID-19 in a major teaching hospital in Europe. 2000 May 6. medRxiv preprint doi:https://doi.org/10.1101/2020.04.29.20080853.
24. Prieto-Alhambra D, Balló E, Coma E, et al. Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases. 2020 May 8. medRxiv preprint doi:https://doi.org/10.1101/2020.05.04.20090050.
25. Regina J, Papadimitriou-Olivgeris M, Burger R, Filippidis P, Tschopp J, Desgranges F. Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study. 2020 May 14. medRxiv preprint doi:https://doi.org/10.1101/2020.05.11.20097741.
26. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region — Case series. N Engl J Med. 2020; DOI: 10.1056/NEJMoa2004500.doi.
27. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19. doi: 10.1001/jama.2020.4326. [Epub ahead of print]
28. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422-426.
29. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020 Apr 24. doi: 10.1001/jama.2020.7202.
30. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464.
31. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 — Georgia, March 2020. MMWR. 2020;69(18):545-550.
32. Richardson S, Hirsch JS, Narasimhan M, et al; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the NewYork City area. JAMA. 2020. doi:10.1001/jama.2020.6775.
33. Paranjpe I, Russak AJ, De Freitas JK, Lala A, Miotto R, Vaid A. Clinical characteristics of hospitalized Covid-19 patients in New York City. 2020 April 26. medRxiv preprint doi: https://doi.org/10.1101/2020.04.19.20062117.
34. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Hamilton GR, et al. Characterization and clinical course of 1000 patients with COVID-19 in New York: retrospective case series. 2020 May 7. medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20072116.
35. Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterisation protocol. medRxiv (2020) doi:10.1101/2020.04.23.20076042.
36. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE; The OpenSAFELY Collaborative. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. 2020 May 7. doi: https://doi.org/10.1101/2020.05.06.20092999. medRxiv preprint.
37. Khawaja AP, Warwick AN, Hysi PG, et al. Associations with covid-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study. 2020 May 11. medRxiv preprint doi: https://doi.org/10.1101/2020.05.06.20092957.
38. Atkins JL, Masoli JÁ, Delgado J, et al. Preexisting comorbidities predicting severe COVID-19 in older adults in the UK Biobank community cohort. 2020 May 8. medRxiv preprint doi: https://doi.org/10.1101/2020.05.06.20092700.
39. Shabrawishi M, Al-Gethamy MM, Naser AY, et al. Clinical, Radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. 2020 May 12. edRxiv preprint doi: https://doi.org/10.1101/2020.05.07.20094169.
40. Carrillo-Veja MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, Parra-Rodríguez L. Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in México. 2020 May 14. medRxiv preprint doi: https://doi.org/10.1101/2020.05.11.20098145.
41. FluView interactive: laboratory-confirmed influenza hospitalizations. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://www.cdc.gov/flu/weekly/ fluviewinteractive.htm ref (Accessed 24-April-2020).
42. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310:1225–1229.
43. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations—a GA2LEN-DARE systematic review. Allergy. 2011;66:458–468.
44. Satia I, Cusack R, Greene JM, O’Byrne PM, Killian KJ, Johnston N. Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma. PLoS One. 2020;15(2):e0228544.
45. Zheng X-Y, Xu Y-J, Guan W-J, Lin L-F. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018;163(4):845-853.
46. van Bever HP, Chng SY, Goh DY. Childhood severe acute respiratory syndrome, coronavirus infections and asthma. Pediatr Allergy Immunol. 2004;15(3):206-209.
47. Tokuhira N, Shime N, Inoue M, et al, Writing Committee of AH1N1 Investigators; Japanese Society of Intensive Care Medicine Pediatric Intensive Care Unit Network. Mechanically ventilated children with 2009 pandemic Influenza A/H1N1: results from the national pediatric intensive care registry in Japan. Pediatr Crit Care Med. 2012;13(5):294-298.
48. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr. 2020 Mar 23. doi: 0.1111/apa.15270.
49. Woodruff PG, Modrek B, Choy DF, et al. T-helper Type 2-driven inflammation defines major subphenotypes of asthma. Am J Resp Crit Care Med. 2009;180:388-395.
50. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.25884.
51. Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma and biologic therapies: what we need to know. World Allergy Organ J. 2020 (in press ).
52. Sajuthi SP, DeFord P, Jackson ND, et al. Type 2 and interferon inflammation strongly regulate SARS- CoV-2 related gene expression in the airway epithelium. bioRxiv 2020.2020.04.09.034454.
53. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol. 2020, doi: https://doi.org/10.1016/j.jaci.200.04.009.
54. Peters MC, Sajuthi S, Deford P, et al. SARS-COV-2 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020 Apr 29. doi: 10.1164/rccm.202003-0821OC.
55. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020. Epub 2020/02/26.
56. Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020:2020.03.11.987016.
57. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv. 2020:2020.03.20.999730.
58. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020 Mar 20. doi: 10.1111/all.14289.
59. Global Initiative for Asthma. 2020 GINA Report, Global Strategy for Asthma Management and Prevention 2020. Available from:www.ginasthma.org (Accessed 28-Apr-2020).
60. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020 Apr 27. pii: 2001009. doi: 10.1183/13993003.01009-2020.
61. Klimek L, Jutel M, Akdis C, at al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Klimek L, Jutel M, Akdis C, at al. Allergy. 2020 Apr 24. doi: 10.1111/all.14336.
62. Bousquet J, Akdis C, Jutel M, et al; ARIA-MASK study group. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 Mar 31. doi: 10.1111/all.14302.
63. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304-309.
64. Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.
65. Levin M, Morais-Almeida M, Ansotegui I, et al. Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organ J. 2020 May 14:100125. doi: 10.1016/j.waojou.2020.100125.
66. Kaye L, Theye B, Smeenk I, Gondalia R, Barrett MA, Stempel DA. J Alllergy Clin Immunol Practice. 2020. https://doi.org/10.1016/j.jaip.2020.04.053.